glp-1 agonist depression Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study GLP-1s: Are We Ignoring the

Examples Canagliflozin (Invokana) Dosage Initial: 100 mg once daily before the first meal of the day Maximum: 300 mg once daily Dapagliflozin (Farxiga) Dosage Initial: 510 mg once daily Maximum: 10 mg once daily Empagliflozin (Jardiance) Dosage Initial: 10 mg once daily Maximum: 25 mg once daily Possible side effects include: Urinary tract infections Genital fungal (mycotic) infections (ie, Candida infection) Hypovolemia (low extracellular fluid) and hypotension (low blood pressure) Acute kidney injury, possibly as a result of volume depletion (limited and contradictory evidence) Diabetic ketoacidosis (rare) Osteoporosis and bone fractures Dipeptidyl peptidase-IV (DPP-4) inhibitors Primary mechanism(s) of action Enhance incretin signaling via inhibition of the enzyme dipeptidyl peptidase-IV (DPP-4), which breaks down GLP-1 and glucose-dependent insulinotropic polypeptide (GIP)

Yes, glutathione and NAD+ can and should be taken together for optimal results

In simple terms, this nutrient assists in transporting fatty acids into your cells mitochondria, where they are converted into energy

ISSN 2213-2317

Pain Relief: LDN is known to reduce pain by blocking the reception of pain signals and increasing endorphins, which naturally alleviate pain

Which Has More Clinical Evidence: NAD+ or Peptide Therapy